Merck Kgaa Unsp ADR (MKGAY) 36.7800 $MKGAY Multiplex

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck Kgaa Unsp ADR (MKGAY) 36.7800 $MKGAY

Multiplex Assays Market Worth USD 3.76 Billion by 2021 - Key Players are Abcam PLC, Illumina & Merck KGAA - Research and Markets
BusinessWire - Mon Aug 08, 10:06AM CDT
Research and Markets has announced the addition of the "Multiplex Assays Market by Product - Global Forecast to 2021" report to their offering.

Merck KGaA / Merck Serono Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:22PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
MRK: 63.04 (-0.28)

New Data at CMSC Assess Real-World Impact of Rebif® (interferon beta-1a) in People with Relapsing MS
PR Newswire - Thu Jun 02, 8:00AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that it will present real-world data that evaluate relapse rates, outcomes of disease activity and healthcare costs in patients initiating Rebif® (interferon beta-1a) at the 2016 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place June 1-4, 2016, in National Harbor, MD.

NCCN Receives Funding for Policy and Advocacy Fellow
Marketwired - Mon May 23, 10:33AM CDT
Through Funding From EMD Serono, NCCN Is Instituting a Policy and Advocacy Fellowship Designed for Implementation of Policy Programs That Will Enhance Access to and Delivery of Quality Oncology Care in the United States and Globally

EMD Serono Supports Military Community By Providing Access to Fertility Care Through Focused Patient Assistance Programs
PR Newswire - Thu May 19, 8:00AM CDT
In recognition of Military Appreciation Month, EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is working to bridge significant gaps in coverage of fertility treatment for eligible active U.S. military and veterans who have been injured in service and are uninsured through its Compassionate Corps and Compassionate Care programs.

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
BusinessWire - Wed May 18, 4:30PM CDT
--Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma
PFE: 34.79 (-0.32)

Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.37 (+0.06), MRK: 63.04 (-0.28)

12th Edition of the EMD Serono Specialty Digest(TM) Now Available
PR Newswire - Mon May 09, 8:44AM CDT
EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced the release of the 12th edition of the EMD Serono Specialty Digest(TM). The Digest, which was featured last week at the Asembia Specialty Pharmacy Summit in Las Vegas, NV, is an industry resource that provides market data on health plans' management of specialty pharmaceuticals in 2015 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.

EMD Serono Expands Biopharmaceutical R&D Facility in Billerica, MA to Accelerate Innovation
PR Newswire - Mon May 02, 6:59AM CDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in North America, today announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.70 (-0.66), CBMG: 13.74 (-0.31), OCAT: 8.47 (+0.01), ZBH: 128.30 (-1.61), PFE: 34.79 (-0.32), LLY: 79.84 (-0.42), GSK: 44.32 (-0.08), GLPG: 53.49 (-0.92), AXSM: 7.32 (+0.31), OMER: 11.31 (-0.20), CANF: 2.21 (-0.04), AST: 2.98 (-0.11), AKTX: 9.81 (+0.46)

Saviynt Selected by the Life Science Business of Merck KGaA, Darmstadt, Germany to Secure Its Next-Generation SAP and S/4HANA Platform
Marketwired - Tue Apr 26, 8:03AM CDT
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, has selected Saviynt to provide security administration, governance and compliance management for its SAP NEXT program. As a company that is laser focused on innovation and quality, this announcement follows the results of an extensive evaluation conducted by Merck KGaA, Darmstadt, Germany for a strategic security solutions partner.

Merck KGaA Selects Unisys to Deliver Global End-User IT Services to Support its Growth Strategy
PR Newswire - Tue Apr 26, 7:00AM CDT
Unisys Corporation (NYSE: UIS) today announced that its subsidiary in Germany has won a new five-year contract to provide Merck KGaA with end-user IT services for its 48,000 employees worldwide.
MRK: 63.04 (-0.28), UIS: 10.50 (-0.11)

EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® (interferon beta-1a) vs. TECFIDERA® (dimethyl fumurate) at AAN Annual Meeting
PR Newswire - Thu Apr 14, 8:00AM CDT
EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced that clinical and real-world data about Rebif® (interferon beta-1a), will be presented at the American Academy of Neurology's (AAN) 68th Annual Meeting, taking place April 15-21, 2016, in Vancouver, BC, Canada. Rebif is the #1 prescribed interferon for patients with relapsing forms of multiple sclerosis (MS) new to therapy and switching therapy combined.+

Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA(R) in Renal Cell Carcinoma
BusinessWire - Tue Apr 05, 7:00AM CDT
--Combination approach leverages Pfizer's broad oncology portfolio and heritage in renal cell carcinoma
PFE: 34.79 (-0.32)

MilliporeSigma's CRISPR Epigenetic Activator Named to The Scientist's Top 10 Innovation List
PR Newswire - Tue Mar 29, 7:00AM CDT
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and, today announced that The Scientist magazine has named the company's CRISPR Epigenetic Activator one of its Top 10 Innovations of 2015.

Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:05PM CST
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon Successful Development and Commercialization of Evofosfamide --
THLD: 0.61 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading